Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Gen-Probe gets rights to Qualigen's platform:

This article was originally published in Clinica

Executive Summary

In what may accelerate its entry into the clinical point-of-care (POC) testing market, nucleic acid test (NAT) maker Gen-Probe has gained exclusive rights to the immunoassay technology behind Qualigen's blood testing system, FastPack. Gen-Probe hopes access to the technology will help it develop a POC NAT system that can identify harmful micro-organisms and genetic mutations, for use in doctors' offices, outpatient clinics and blood screening centres. The San Diego, California firm will pay Qualigen an initial $1m for an 18-month option to license on an exclusive basis.





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts